(STTK) Shattuck Labs, Inc. Business Model Canvas Research

Shattuck Labs, Inc. depends on contract manufacturing organizations to make preclinical and clinical biologic supply under GMP rules, then support lot release before each trial batch. These partners matter most before late-stage scale-up, because CMO capacity and quality systems often decide whether supply is ready on time.

Shattuck Labs, Inc. must stay in close contact with FDA and site IRBs during Phase 1, where every protocol change, safety signal, and dosing decision can affect approval speed. These bodies shape study design, serious adverse event reporting, and the path to later labeling, so compliance is a daily operating need, not a one-time step.

• FDA and IRBs gate trial start
• Phase 1 needs constant reporting
• Safety rules shape labels later

Shattuck Labs, Inc. must keep clinical candidates available for every dose and test, so CMC work covers release testing, stability, and batch control. In multi-site trials, supply coordination links manufacturing, packaging, and shipment timing so each site gets matched drug on time; even one missed batch can delay dosing and data readouts.

• Batch release protects quality and stability
• Cold-chain supply supports site dosing
• Multi-site timing prevents trial delays

Scientific and regulatory documentation is a core biotech task for Shattuck Labs, Inc.: IND packages, study reports, and updates must show safety, pharmacology, and dose rationale before human testing can move ahead. For clinical-stage biotech, this is a recurring operating need, not a one-off job.

Each filing turns lab data into regulator-ready evidence, so the work directly shapes trial speed and capital use. The company’s documentation team supports the full path from preclinical package to ongoing study reporting.

• IND-ready safety data
• Pharmacology and dosing support
• Recurring study reports

Shattuck Labs, Inc., founded in 2016, keeps its Austin, Texas headquarters as the control point for corporate, scientific, and investor work. Centralized leadership helps align governance, capital planning, and R&D decisions for a clinical-stage biotech with no product revenue in 2025.

• Founded in 2016
• Austin HQ supports key functions
• Centralized oversight aids planning

Shattuck Labs, Inc.’s key resources are its drug candidates and the platform know-how behind them. Patent coverage and proprietary research data help protect that IP moat, which matters most before any approved product revenue arrives.

• Drug candidates = core intangible assets
• Patents back competitive advantage
• Data moat matters pre-revenue

Shattuck Labs, Inc. centers its value proposition on immune-based therapeutics that aim to modulate disease pathways in ways standard chemotherapy cannot. That can support cleaner mechanism-based efficacy and make combination use more attractive in oncology and inflammation.

• Immune modulation can be more targeted.
• May improve combo-therapy fit.
• Built on innovative therapeutic science.

Shattuck Labs, Inc.'s value here is partnerable clinical assets like SL-172154, which can interest larger biopharma before approval because they already have human data and can be licensed or co-developed. That gives Shattuck Labs, Inc. cash and strategic optionality now, while keeping upside if a program advances.

• Clinical data can trigger partner interest
• Early deals lower funding risk
• Co-development keeps commercialization upside

Shattuck Labs, Inc. uses conferences and research channels to share early trial data, which helps build credibility for emerging clinical assets and invites peer review before larger readouts. In 2025-2026, that kind of scientific visibility is key for biotech firms because trust often forms before revenue does.

• Shares data through conferences
• Builds credibility early
• Supports peer review

Partner development discussions are key for Shattuck Labs, Inc. because licensing and collaboration decisions in biotech hinge on clean data and clinical readouts, not speed. Large pharma teams often screen a pipeline across preclinical to Phase 1/2 milestones, so these talks can run for quarters before any term sheet.

• Data first, deal later
• Pharma reviews pipeline depth
• Long cycle, milestone-driven

Shattuck Labs, Inc. uses scientific conferences to share early clinical data with medical and scientific audiences, especially Phase 1 readouts and mechanism-of-action findings for its pipeline. Publications then extend that reach and build credibility beyond the conference cycle.

• Phase 1 data first
• Mechanism insights at congresses
• Publications boost visibility

That mix helps turn trial updates into peer-reviewed proof points, which matters when a platform company is still building awareness and scientific trust.

Business development outreach is a key channel for Shattuck Labs, Inc. because partner talks can turn pre-approval science into cash, shared risk, and licensing or co-development deals. In biotech, this matters early: 2025 dealmaking stayed active even as capital stayed tight, so a strong outreach lane can speed value capture before product approval.

• Drives licensing and collaboration talks

• Helps monetize assets before approval

Oncologists and hematologists are core customer segments for Shattuck Labs, Inc. because they identify eligible patients, run trials, and shape referral flow. In biotech, physician participation can decide whether studies enroll fast enough; in 2025, that matters even more as Shattuck Labs, Inc. advances a small pipeline and depends on expert site-level execution.

• Find eligible patients
• Run trial sites
• Drive scientific trust
• Influence referrals

Their buy-in affects data quality, enrollment speed, and later adoption, so these specialists are both users and gatekeepers for Shattuck Labs, Inc.'s clinical programs.

Biopharma partners are a core customer segment for Shattuck Labs, Inc. because a clinical-stage biotech’s future value often comes from licensing or collaboration with larger drug makers that can fund late-stage trials, scale development, and validate pipeline quality. These partners judge the science, target fit, and clinical progress before paying for access.

• Drives licensing and collaboration value
• Signals pipeline quality to the market
• Helps fund later-stage development

Shattuck Labs' regulatory and quality costs fund IND maintenance, safety reporting, and quality systems, so they stay necessary even before sales begin. For a clinical-stage biotech, this spend also includes regulatory consultants and compliance checks that sit in R&D and G&A overhead.

• IND upkeep and safety reporting
• Compliance consultants add overhead
• Quality systems are required spend

Shattuck Labs, Inc. General and administrative costs cover its Austin headquarters, finance, legal, and investor relations teams, plus the reporting and audit work tied to being a public company. These costs support the corporate structure and usually rise with SEC filing and compliance load.

• Austin HQ overhead
• Finance, legal, investor relations
• Public-company reporting and audit costs

Future royalties could become a revenue stream if a partnered asset reaches approval and then generates net sales, because Shattuck would earn a percentage of those sales after launch. This model adds long-term upside, but only after successful clinical and regulatory progress; as of the latest public filings, Shattuck Labs had not yet reported royalty income.

• Triggered only after approval
• Based on net sales
• No royalty cash yet reported

Shattuck Labs, Inc. relies on equity financing because clinical-stage biotechs usually have $0 product revenue before approval, so stock offerings and capital raises fund R&D, trials, and G&A. The model is cash-intensive and development-led, with value tied to pipeline milestones rather than near-term sales.

• Funds trials before product sales
• Supports high R&D cash burn
• Dilution is the main tradeoff